Drug Trial Radar · NCT02343458
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Last checked: Nov 19, 2026Latest source record: Feb 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,756
Actual
Start
Mar 30, 2015
Primary completion
Aug 31, 2017
Study completion Aug 31, 2017
Sponsor
- Lead sponsor
- Pearl Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003)Drug
Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
FF MDI (PT005)Drug
Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
GP MDI (PT001)Drug
Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Placebo MDIDrug
Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)Time frame: at week 24
- Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan ApproachTime frame: over weeks 12-24
- Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.Time frame: over 24 weeks
Locations
166 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Andalusia, Alabama
Research Site
Birmingham, Alabama
Research Site
Foley, Alabama
Research Site
Jasper, Alabama
Research Site
Anaheim, California
Research Site
Boulder, Colorado
Research Site
Clearwater, Florida
Research Site
Clearwater, Florida
Research Site
Kissimmee, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Panama City, Florida
Research Site
Pensacola, Florida
Research Site
Tamarac, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Atlanta, Georgia
Research Site
Blue Ridge, Georgia
Research Site
North Dartmouth, Massachusetts
Research Site
Edina, Minnesota
Research Site
Fridley, Minnesota
Research Site
Minneapolis, Minnesota
Research Site
Woodbury, Minnesota
Research Site
Saint Charles, Missouri
Research Site
St Louis, Missouri
Research Site
Gastonia, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Columbus, Ohio
Research Site
Dayton, Ohio
Research Site
Dayton, Ohio
Research Site
Dublin, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Medford, Oregon
Research Site
Easley, South Carolina
Research Site
Gaffney, South Carolina
Research Site
Greenville, South Carolina
Research Site
Rock Hill, South Carolina
Research Site
Seneca, South Carolina
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.